A Look At Xenon Pharmaceuticals (XENE) Valuation After Strong Long Term Returns And Recent Momentum Cooldown
Xenon Pharmaceuticals (XENE) has shown strong long-term returns but recent momentum has cooled, leading to questions about its current valuation. Despite no revenue and ongoing losses, a narrative suggests the stock is 45.9% undervalued with a fair value of $100.00 per share, driven by its late-stage neurology programs and ambitious earnings expectations. However, this bullish outlook is contingent on successful clinical trials and avoiding shareholder dilution.
5 Best Performing Canadian Stocks So Far in 2026
This article identifies Xenon Pharmaceuticals Inc. (NASDAQ:XENE) as one of the best-performing Canadian stocks in 2026. Analysts from JPMorgan and Wells Fargo raised price targets on XENE, maintaining Overweight ratings due to positive Phase 3 data for azetukalner in focal onset seizures. The company's Q1 2026 earnings exceeded expectations, and management plans to submit a New Drug Application to the FDA in Q3 2026, with cash reserves expected to cover operations until 2029.
Xenon Pharmaceuticals stock (CA98420N1050): epilepsy data and capital raise put biotech in focus
Xenon Pharmaceuticals has attracted investor attention due to recent epilepsy trial data and a capital raise, positioning the neurology-focused biotech in the spotlight for US investors. The company focuses on developing therapeutics for neurological conditions, especially epilepsy, by targeting ion channels. While relying on clinical programs and capital markets for funding, its success hinges on future clinical, regulatory, and financing milestones.
DNB Asset Management AS Acquires 23,750 Shares of Xenon Pharmaceuticals Inc. $XENE
DNB Asset Management AS increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 9.5% in the fourth quarter, purchasing an additional 23,750 shares to now own a total of 272,831 shares valued at approximately $12.2 million. Institutional investors collectively hold 95.45% of the company's stock, with other major firms like Goldman Sachs and Alliancebernstein also boosting their positions. Despite the biopharmaceutical company continuing to post losses, analysts maintain a "Buy" rating with an average price target of $77.07, significantly higher than its current closing price of $54.39.
(XENE) Volatility Zones as Tactical Triggers
This article from Stock Traders Daily discusses Xenon Pharmaceuticals (NASDAQ: XENE), highlighting weak near-term sentiment but potential long-term strength. It outlines various trading strategies leveraging AI-generated signals and risk management parameters for different risk profiles. The analysis points out testing resistance and offers an exceptional risk-reward short setup.
Janus Henderson reports 4.5% stake in Xenon Pharmaceuticals (XENE) filing
Janus Henderson Group plc, through its asset managers, has reported a 4.5% beneficial ownership stake in Xenon Pharmaceuticals Inc. (XENE), totaling 4,175,982 common shares. This holding is for managed portfolios, with Janus Henderson's asset managers exercising shared voting and dispositive power, but not receiving dividends or proceeds from sales. The filing emphasizes that this is a passive investment, with no single managed portfolio owning more than 5%.
Driehaus files Schedule 13G/A disclosing 4.87% in Xenon (XENE)
Driehaus Capital Management LLC has filed a Schedule 13G/A, reporting a 4.87% beneficial ownership stake in Xenon Pharmaceuticals Inc. (XENE). As of December 31, 2025, Driehaus held 4,491,653 shares with shared voting and dispositive power, classifying this as a passive investment. The amendment was signed on May 15, 2026, by Janet McWilliams, General Counsel.
Xenon Q1 earnings match estimates, pipeline development in focus
Xenon Pharmaceuticals reported first-quarter earnings that were in line with analyst estimates. The company provided updates on its clinical development pipeline, highlighting progress across its neurology and dermatology programs. The primary focus remains on advancing its lead drug candidates through clinical trials and toward potential market approval.
A Look At Xenon Pharmaceuticals (XENE) Valuation After Phase III Azetukalner Milestones And Extended Cash Runway
Xenon Pharmaceuticals (XENE) recently announced positive Phase III data for azetukalner in epilepsy, with an NDA filing expected in Q3 2026 and a clear commercial launch timeline, alongside an extended cash runway. Despite recent short-term share price drops, the stock has shown strong annual growth, and analysts suggest it is currently undervalued with a fair value target of $100. The company's diverse ion channel pipeline further strengthens its future earnings potential and reduces reliance on a single asset.
Xenon Pharmaceuticals (XENE) director exercises options, now holds 10,641 shares
Xenon Pharmaceuticals Inc. director Steven Gannon exercised stock options to acquire 3,500 Common Shares at an exercise price of $7.38 per share. This transaction increased his direct holdings to 10,641 Common Shares, with no related options from this grant remaining outstanding. The exercise-and-hold transaction indicates a routine conversion of fully vested derivative securities into directly held stock.
Insiders At Xenon Pharmaceuticals Sold US$1.0m In Stock, Alluding To Potential Weakness
The article reports that insiders at Xenon Pharmaceuticals sold US$1.0 million worth of company stock. This significant insider selling could suggest a lack of confidence in the company's future performance or that the stock is currently overvalued, potentially indicating weakness.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) held its Q1 2026 earnings call, reporting EPS inline with expectations at $-1.17. The company highlighted significant progress, including positive Phase 3 XTOL-2 study results for azetucalder (AZK) in focal onset seizures, with an NDA submission anticipated in 2026. Xenon also outlined plans for AZK in neuropsychiatric indications with Phase 3 depression studies, and advanced its early-stage pain programs, fueled by a $747.5 million financing extending its cash runway into 2029.
Is It Too Late To Consider Xenon Pharmaceuticals (XENE) After A 58% One-Year Surge?
Xenon Pharmaceuticals (XENE) has seen a significant 58% surge over the last year, prompting a valuation analysis. A Discounted Cash Flow (DCF) model suggests the stock is 82.1% undervalued with an estimated intrinsic value of $312.27 per share against its current price of around $56. While its Price to Book (P/B) ratio of 9.30x is above the biotech industry average, it's below its peer group, and further analysis using the proprietary Fair Ratio would be needed for a definitive P/B valuation.
Xenon Q1 Earnings Match Estimates, Pipeline Development in Focus
Xenon Pharmaceuticals reported a Q1 2026 loss of $1.17 per share, matching estimates, and generated no revenues as it lacks a marketed product. The company's R&D expenses increased due to ongoing late-stage studies for azetukalner in epilepsy, MDD, and BPD, and it boasts a strong cash position expected to support operations into 2029. Xenon also announced positive Phase III data for azetukalner in focal onset seizures and plans an FDA submission in Q3 2026, alongside other pipeline advancements.
Xenon Pharmaceuticals Q1 Loss Widens
Xenon Pharmaceuticals reported a wider net loss of $59.5 million for Q1 2026, compared to $44.5 million in Q1 2025. This increase was primarily due to higher research and development expenses, which rose to $53.0 million, and general and administrative expenses, which increased to $15.0 million. The company's cash and cash equivalents stood at $580.4 million as of March 31, 2026.
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Inc. reported its Q1 2026 financial results, highlighting positive topline data from its Phase 3 X-TOLE2 study of azetukalner for focal onset seizures (FOS) and plans for an NDA submission in Q3 2026. The company also announced that five additional Phase 3 studies for azetukalner are ongoing in epilepsy and depression, with topline data for MDD expected in H1 2027. Xenon's cash, cash equivalents, and marketable securities total $1.3 billion, extending its cash runway into 2029.
Xenon Pharmaceuticals 1Q Rev $0.00 >XENE
Xenon Pharmaceuticals reported $0.00 in revenue for its first quarter. This financial update indicates no revenue generation for the period.
Earnings Flash (XENE) Xenon Pharmaceuticals Posts Q1 Per Share Loss $1.17, vs. FactSet Est of Loss $1.18
Xenon Pharmaceuticals (XENE) reported a Q1 per share loss of $1.17, which was slightly better than FactSet's estimated loss of $1.18. This financial update was published on May 7, 2026. The company is actively developing therapeutics for neurological and psychiatric disorders, with a lead compound, Azetukalner, in late-stage clinical development for epilepsy and major depressive disorder.
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Inc. reported its Q1 2026 financial results, highlighting positive topline data from its Phase 3 X-TOLE2 study for azetukalner in focal onset seizures, with an NDA submission anticipated in Q3 2026. The company's cash reserves of $1.3 billion extend its cash runway into 2029, supporting ongoing Phase 3 trials for azetukalner in epilepsy and depression, as well as early-stage programs for pain. Xenon also reported an increased net loss for the quarter, largely due to higher R&D and general administrative expenses.
Xenon Pharmaceuticals: Q1 Earnings Snapshot
Xenon Pharmaceuticals Inc. (XENE) reported a first-quarter loss of $102.3 million, or $1.17 per share. This result matched the expectations of Wall Street analysts surveyed by Zacks Investment Research. The company is based in Burnaby, British Columbia.
Big cash raise and strong Phase 3 results headline Xenon (XENE) Q1 2026
Xenon Pharmaceuticals reported a wider net loss in Q1 2026, totaling $102.3 million, compared to $65.0 million a year ago, primarily due to increased R&D and G&A expenses and the absence of prior collaboration revenue. Despite the loss, the company significantly strengthened its balance sheet, raising $837.6 million through equity offerings, bringing cash, cash equivalents, and marketable securities to $1.34 billion, extending its cash runway into 2029. Key progress includes positive Phase 3 X-TOLE2 data for azetukalner in focal onset seizures, with plans for an NDA submission in Q3 2026, alongside ongoing Phase 3 studies in epilepsy and mood disorders and advancing Phase 1 pain programs.
Xenon Reports Q1 2026 Financial Results and Provides Business Update
Xenon Pharmaceuticals Inc. announced its Q1 2026 financial results, highlighted by positive Phase 3 X-TOLE2 study data for azetukalner in FOS, leading to an anticipated NDA submission in Q3 2026. The company reported a strong cash position of $1.3 billion, extending its cash runway into 2029, and is advancing multiple other clinical programs for azetukalner in epilepsy and depression, and early-stage pain candidates.
Xenon Pharmaceuticals faces earnings test as launch nears By Investing.com
Xenon Pharmaceuticals Inc. is set to report first-quarter earnings, with investors keenly watching its cash position and commercialization plans for its lead drug, azetukalner, which is nearing an FDA application. The company is expected to post its first quarterly revenue, along with a narrower loss per share compared to the previous quarter. Key investor concerns include the cash runway, building commercial infrastructure for an independent launch, and updates on regulatory timelines for azetukalner.
Xenon Pharmaceuticals: Q1 Earnings Snapshot
Xenon Pharmaceuticals Inc. (XENE) reported a first-quarter loss of $102.3 million, translating to $1.17 per share. This financial result matched the expectations of Wall Street analysts, with the average estimate from eight analysts also predicting a loss of $1.17 per share. The data for this report was generated by Automated Insights using information from Zacks Investment Research.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to seven new non-officer employees, totaling 25,600 share options and 15,000 restricted share units (RSUs). These grants, approved by the Compensation Committee with an effective date of April 30, 2026, were made as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $56.04 and vest over four years, while the RSUs also vest over four years, both subject to continued employment with the company.
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to seven new non-officer employees, totaling 25,600 share options and 15,000 restricted share units (RSUs). These grants, with an effective date of April 30, 2026, were made as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options have an exercise price of $56.04 and vest over four years, similar to the RSUs which also vest over four years.
Seven new Xenon hires get stock awards priced on $56.04
Xenon Pharmaceuticals announced inducement equity grants to seven new non-officer employees, totaling 25,600 share options and 15,000 restricted share units (RSUs). The share options have an exercise price of $56.04, matching the closing price on April 30, 2026, and vest over four years, while RSUs also vest over four years. These grants were approved by the Compensation Committee under Nasdaq Listing Rule 5635(c)(4).
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals Inc. announced equity inducement grants to seven new non-officer employees, totaling 25,600 share options and 15,000 restricted share units (RSUs). These grants, approved by the Compensation Committee with an effective date of April 30, 2026, serve as inducements for employment in accordance with Nasdaq Listing Rule 5635(c)(4). The share options and RSUs have specific vesting schedules and terms outlined under the company's 2025 Inducement Equity Incentive Plan.
Jennison Associates LLC Boosts Stock Position in Xenon Pharmaceuticals Inc. $XENE
Jennison Associates LLC increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 13.8% in Q4, acquiring an additional 156,820 shares, bringing their total to 1,292,055 shares valued at $57.91 million. Several other institutional investors also increased their holdings, leading to institutional ownership of 95.45% in the biopharmaceutical company. Despite this, insiders sold approximately 296,707 shares worth $17.85 million, and the company reported a Q4 EPS miss, remaining unprofitable.
Pictet Asset Management Holding SA Cuts Position in Xenon Pharmaceuticals Inc. $XENE
Pictet Asset Management Holding SA reduced its stake in Xenon Pharmaceuticals Inc. by 50.4% in Q4, selling 636,594 shares. Despite this, other institutional investors have increased their positions in the biopharmaceutical company. Analysts widely rate Xenon Pharmaceuticals as a "Buy" with a consensus price target of $73.13, although the company recently missed its quarterly EPS estimates.
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals Inc. announced it will report its first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, after the U.S. financial markets close. The company will host a presentation at 4:30 PM ET, accessible via webcast and dial-in. Xenon is a neuroscience-focused biopharmaceutical company with lead molecules in Phase 3 clinical trials for epilepsy and mood disorders, and early-stage programs for pain.
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals Inc. announced it will report its first-quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, after the close of U.S. financial markets. A live webcast and dial-in details have been provided for an accompanying company presentation. Xenon is a neuroscience-focused biopharmaceutical company with lead molecule azetukalner in Phase 3 clinical trials for epilepsy, major depressive disorder, and bipolar depression.
May 7 after the bell: Xenon to give Q1 update, host webcast
Xenon Pharmaceuticals (Nasdaq: XENE) will report its Q1 2026 financial results and provide a business update on May 7, 2026, after the U.S. markets close at 4:30 PM ET. The company will host a live webcast and conference call to discuss its performance and pipeline, including its lead molecule azetukalner which is in Phase 3 trials for several neurological and mood disorders. Investors are expected to focus on management's plans for cash usage and development timelines for its various programs.
Xenon to Report Q1 2026 Financial Results on May 7, 2026
Xenon Pharmaceuticals Inc. announced it will report its first-quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, after the close of U.S. financial markets. The company presentation will include a live webcast accessible through Xenon's website. Xenon is a neuroscience-focused biopharmaceutical company with its lead molecule, azetukalner, in Phase 3 clinical trials for epilepsy, MDD, and bipolar depression.
XENE Price Today: Xenon Pharmaceuticals Inc. Stock Price, Quote & Chart | MEXC
Xenon Pharmaceuticals Inc. (XENE) is currently trading at $55.23, reflecting a -0.32% change from its previous close. The stock has shown strong performance over the last year with a +45.97% price change, despite a short-term decline of -0.57% over the past four weeks. The article provides key market data, trading instructions, company information, and an extensive FAQ section for investors.
Peregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENE
Peregrine Capital Management LLC initiated a new position in Xenon Pharmaceuticals Inc. by purchasing 174,851 shares valued at approximately $7.84 million during the fourth quarter, bringing institutional ownership to about 95.45%. Analysts maintain a "Buy" consensus rating with an average price target of $73.13, despite recent insider selling totaling approximately $17.8 million. The company's stock has shown recent price performance, but insiders have reduced their holdings, now owning about 4.07%.
[ARS] Xenon Pharmaceuticals Inc. SEC Filing
This article announces an ARS SEC filing by Xenon Pharmaceuticals Inc. (XENE) on April 22, 2026, which is available as a PDF document. It also provides an overview of Xenon's stock data, recent news, and other SEC filings, highlighting the company's market cap and clinical study updates. The filing has a low impact and neutral sentiment.
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB)
Myles Minter from William Blair reiterated a Buy rating on Xenon (XENE) with a Strong Buy consensus and an average price target of $75.82. Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB) with a price target of $231.00, contributing to a Moderate Buy consensus and a $206.61 average price target. Piper Sandler also upgraded Biogen to Buy with a $214.00 price target.
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial By Investing.com
Xenon Pharmaceuticals' azetukalner demonstrated a significant reduction in monthly seizure frequency, with a 53.2% decrease in the 25 mg group during its Phase 3 X-TOLE2 study. The positive trial results, presented at the American Academy of Neurology Annual Meeting, have led to a 70% surge in the company's stock over the past year and raised approximately $747.5 million in a recent public offering, extending its cash runway. Xenon plans to submit a New Drug Application to the FDA in Q3 2026 for azetukalner, a KV7 potassium channel opener.
Needham Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $80
Needham has reiterated its Buy rating for Xenon Pharmaceuticals (XENE.US) and maintained its price target of $80. This indicates a continued positive outlook from the analyst firm on the company's prospects.
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Xenon Pharmaceuticals presented positive Phase 3 X-TOLE2 study results and 48-month long-term data for azetukalner in focal onset seizures at the 2026 AAN Annual Meeting. The data showed significant reductions in seizure frequency, with 53.2% in the 25 mg group versus 10.4% for placebo, and impressive rates of seizure freedom over time in the long-term open-label extension study. Real-world data also highlighted the value of anti-seizure medications that do not require titration, reinforcing azetukalner's potential benefits for patients and physicians.
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial
Xenon Pharmaceuticals Inc. announced positive Phase 3 X-TOLE2 study results for its drug azetukalner, showing a 53.2% reduction in monthly seizure frequency for the 25 mg dose group in adults with focal onset seizures. The company plans to submit a New Drug Application to the FDA in the third quarter of 2026. This news has led to increased market confidence, a 70% stock surge over the past year, and positive analyst revisions projecting significant upside.
Xenon Pharma’s azetukalner shows 53% seizure reduction in trial By Investing.com
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) reported positive Phase 3 X-TOLE2 study results for its drug azetukalner, showing a significant 53.2% reduction in monthly seizure frequency for the 25 mg group compared to placebo in adults with focal onset seizures. The company plans to submit a New Drug Application to the FDA in Q3 2026. Financial analysts have reacted positively, with Wedbush and BofA Securities raising price targets for XENE after the successful trial.
RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug
RBC Capital has increased its price target for Xenon Pharmaceuticals (XENE) to $60, maintaining an "Outperform" rating. The adjustment reflects RBC's increased confidence in the Phase III pipeline candidate XEN1101 for focal epilepsy, following positive Phase IIb data. RBC anticipates a successful Phase III outcome, positioning XEN1101 to capture a significant share of the epilepsy market, potentially reaching $1 billion in peak sales.
Assessing Xenon Pharmaceuticals (XENE) Valuation After Strong Recent Share Price Momentum
Xenon Pharmaceuticals (XENE) has seen significant share price growth recently, with returns of 8.4% over the past month and 49.3% over three months. The company is currently valued at US$5.6 billion and trades at US$59.70, prompting questions about its valuation. Analysts have a diverse view, with a common narrative suggesting a fair value of $100, while others express caution due to its high Price-to-Book (P/B) ratio compared to the industry and its current loss-making status.
Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. announced its participation in four investor conferences during the second quarter of 2026. The neuroscience-focused biopharmaceutical company will present at events hosted by Bloom Burton & Co., Bank of America, RBC Capital Markets, and Jeffries, providing updates on its drug discovery and clinical development programs. Details regarding presentation schedules and webcasts are available on the investors section of Xenon's website.
Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)
Xenon Pharmaceuticals (NASDAQ:XENE) experienced unusually large options trading activity, with traders acquiring 4,063 put options, representing a 2,362% increase over the average daily volume. This comes amidst a "Buy" consensus rating from analysts but with significant insider selling totaling $17.85 million over the past three months and a recent quarterly EPS miss. The company, a clinical-stage biopharmaceutical firm, focuses on developing drugs for neurological and pain disorders.
Xenon lines up four investor conference presentations in Q2 2026
Xenon Pharmaceuticals (NASDAQ: XENE) announced its schedule to present at four investor conferences in Q2 2026, including the Bloom Burton, Bank of America, RBC Capital Markets, and Jeffries Global Healthcare Conferences. The presentations will cover updates on their lead molecule azetukalner, which is in Phase 3 trials for epilepsy and mood disorders, and other early-stage potassium and sodium channel modulators. Webcast details and replays will be available on the company's investors section.
Xenon to Present at Upcoming Investor Conferences
Xenon Pharmaceuticals Inc. announced its participation in four upcoming investor conferences during the second quarter of 2026. The neuroscience-focused biopharmaceutical company will present at the Bloom Burton & Co. Healthcare Investor Conference, Bank of America Global Healthcare Conference, RBC Capital Markets Global Healthcare Conference, and Jeffries Global Healthcare Conference. Details and webcasts for these presentations will be available on Xenon's investor relations website.
Xenon Pharmaceuticals (XENE) boosts 2025 inducement equity plan share reserve
Xenon Pharmaceuticals Inc. (XENE) has amended its 2025 Inducement Equity Incentive Plan, increasing the share reserve for new-hire equity awards from 900,000 to 1,175,000 common shares. This change, which did not require shareholder approval per Nasdaq Listing Rule 5635(c)(4), is intended to incentivize individuals being hired or rehired by Xenon and its subsidiaries through various equity instruments like stock options and restricted stock units. The amendment was made on April 7, 2026.
